We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Proteins Identified in Metastatic Kidney Cancer

By LabMedica International staff writers
Posted on 20 Dec 2012
A unique set of proteins have been analyzed that are likely to be involved in the spread of metastatic renal cell carcinoma (RCC). More...


The discovery will help physicians recognize which tumors are going to behave more aggressively and provide those patients with more intensive treatment and closer follow-up.

Scientists collaborating with pathologists at St. Michael's Hospital (Toronto, ON, Canada) used differential proteomics with isobaric tags for relative and absolute quantitation (iTRAQ) labeling and liquid chromatography and mass spectrometry (LC-MS/MS) analysis to identify proteins that are differentially expressed in metastatic compared to primary RCC. Primary RCC tissues and matched normal kidney tissues from the same patient were obtained from nephrectomy specimens at the hospital and processed.

Western blot analysis, tissue microarray construction and immunohistochemistry were also performed. The team identified 29 proteins that change when cancer cells spread from the original site of the kidney tumor and all 29 proteins have been previously been linked to other malignancies. Of these, 12 were overexpressed (iTRAQ ratios of equal or greater than 1.5) and 17 were under expressed (iTRAQ ratios of equal to or less than 0.67).

The authors concluded that through quantitative proteomic analysis, they had identified differential protein expressions that can distinguish between aggressive and nonaggressive RCC tumors. Many of these proteins are involved in biological pathways pertinent to tumor progression and metastasis. In addition, their preliminary analysis showed that some of these dysregulated proteins may be useful clinical markers and validation of these markers would greatly improve RCC patient treatment and increase overall survival.

George M. Yousef, MD, PhD, the senior author of the study, said “Metastatic renal cell carcinoma is one of the most treatment-resistant malignancies and patients have dismal prognosis. Identification of markers that can predict the potential of metastases will have a great impact on improvement patient outcomes." The study was published on October 17, 2012, in the journal Molecular & Cellular Proteomics.

Related Links:

St. Michael's Hospital




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.